Literature DB >> 19004932

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.

María José Soler1, Minghao Ye, Jan Wysocki, Josette William, Josep Lloveras, Daniel Batlle.   

Abstract

Angiotensin-converting enzyme (ACE)2 is a carboxypeptidase that degrades angiotensin II and other peptides. In the kidney, ACE2 localization within the glomerulus and tubules is cell specific. This study was aimed to investigate the localization of ACE2 within the renal vasculature. We also studied the effect of the administration of a specific angiotensin II type 1 receptor blocker, telmisartan, on ACE2 expression in the renal vasculature. ACE2 and ACE were localized in renal arterioles using confocal microscopy and specific cell markers. Quantitative measurements of ACE2 and ACE mRNA were estimated in kidney arterioles isolated by laser capture microdissection using real-time PCR. In kidney arterioles, ACE was localized in the endothelial layer, whereas ACE2 was localized in the tunica media. In mice treated with telmisartan (2 mg.kg(-1).day(-1)) for 2 wk, ACE2 expression was increased by immunostaining, whereas ACE expression was decreased. This was reflected in a decrease in the ACE/ACE2 ratio compared with vehicle-treated controls (0.53 +/- 0.14 vs. 7.59 +/- 2.72, P = 0.027, respectively). In kidney arterioles isolated by laser capture microdissection, the ACE/ACE2 mRNA ratio was also decreased compared with control mice (1.21 +/- 0.31 vs. 4.63 +/- 0.86, P = 0.044, respectively). In conclusion, in kidney arterioles ACE2 is preferentially localized in the tunica media, and its expression is increased after administration of the angiotensin II type 1 receptor blocker, telmisartan. Amplification of ACE2 in the renal vasculature may contribute to the therapeutic action of telmisartan by increasing angiotensin II degradation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004932     DOI: 10.1152/ajprenal.90488.2008

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  97 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 2.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

3.  Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.

Authors:  Jan Wysocki; Enrique Lores; Minghao Ye; Maria Jose Soler; Daniel Batlle
Journal:  J Am Soc Nephrol       Date:  2020-07-15       Impact factor: 10.121

Review 4.  The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.

Authors:  Carlos M Ferrario; Jasmina Varagic
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

5.  Enzymatic processing of angiotensin peptides by human glomerular endothelial cells.

Authors:  Juan Carlos Q Velez; Jessalyn L Ierardi; Alison M Bland; Thomas A Morinelli; John M Arthur; John R Raymond; Michael G Janech
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-28

6.  Divergent localization of angiotensinogen mRNA and protein in proximal tubule segments of normal rat kidney.

Authors:  Masumi Kamiyama; Kristina M Farragut; Michelle K Garner; L Gabriel Navar; Hiroyuki Kobori
Journal:  J Hypertens       Date:  2012-12       Impact factor: 4.844

7.  Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19.

Authors:  Henry Sackin
Journal:  Med Hypotheses       Date:  2021-05-12       Impact factor: 1.538

8.  Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries.

Authors:  Phillip G Kopf; William B Campbell
Journal:  Endocrinology       Date:  2013-10-03       Impact factor: 4.736

Review 9.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

10.  Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.

Authors:  Elena Velkoska; Rachael G Dean; Luke Burchill; Vicki Levidiotis; Louise M Burrell
Journal:  Clin Sci (Lond)       Date:  2010-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.